Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017152270) USE OF PNEUMOLYSIN PEPTIDES AS ANTAGONISTS AGAINST TOLL-LIKE RECEPTOR 4 AND METHODS OF TREATING TOLL-LIKE RECEPTOR 4 RELATED DISEASES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/152270 International Application No.: PCT/CA2017/050238
Publication Date: 14.09.2017 International Filing Date: 24.02.2017
IPC:
C07K 14/315 (2006.01) ,A61K 35/74 (2015.01) ,A61K 38/16 (2006.01) ,A61P 3/10 (2006.01) ,C07K 7/06 (2006.01) ,C12N 15/31 (2006.01) ,C12N 15/85 (2006.01)
[IPC code unknown for C07K 14/315][IPC code unknown for A61K 35/74][IPC code unknown for A61K 38/16][IPC code unknown for A61P 3/10][IPC code unknown for C07K 7/06][IPC code unknown for C12N 15/31][IPC code unknown for C12N 15/85]
Applicants:
KEMYTH BIOTECH CO., LTD. [CN/CN]; 4F.-2, No. 91, Sec. 2 Roosevelt Rd., Da'an Dist. Taipei City 10646, TW
Inventors:
SIU, Leung-Kei; TW
CHANG, Feng-Yee; TW
LENG, Chih-Hsiang; TW
CHONG, Pele Choi-Sing; CA
Agent:
TOO, Constance; CA
HARRIS, John; CA
ROY, Matthew; CA
BAKER, James; CA
NEWTON, Trevor; CA
LEDWELL, Kent; CA
MORI, Sumiko; CA
O'NEILL, Kevin; CA
WILKIE, Jennifer; CA
SPRIGINGS, Mark; CA
Priority Data:
62/305,16408.03.2016US
Title (EN) USE OF PNEUMOLYSIN PEPTIDES AS ANTAGONISTS AGAINST TOLL-LIKE RECEPTOR 4 AND METHODS OF TREATING TOLL-LIKE RECEPTOR 4 RELATED DISEASES
(FR) UTILISATION DE PEPTIDES DE PNEUMOLYSINE EN TANT QU'ANTAGONISTES CONTRE LE RÉCEPTEUR 4 DE TYPE TOLL ET MÉTHODES DE TRAITEMENT DES MALADIES LIÉES AU RÉCEPTEURS 4 DE TYPE TOLL
Abstract:
(EN) The present invention relates to isolated peptides from pneumolysin (PLY ) and their use as antagonists of toll-like receptor 4 (TLR-4). Bind of said peptides results in decreased activity of TLR-4. Particularly, the present invention provides isolated peptides from the C-terminal region of PLY which are effective in treatment of TLR-4 related activation conditions such as diabetes and atherosclerosis.
(FR) La présente invention concerne des peptides isolés à partir de la pneumolysine (PLY) et leur utilisation en tant qu'antagonistes contre le récepteur 4 de type toll (TLR-4). La liaison de ces peptides entraîne une activité diminuée de TLR-4. En particulier, la présente invention concerne des peptides isolés provenant de la région C-terminale de PLY qui sont efficaces dans le traitement de pathologies d'activation liées à TLR-4 telles que le diabète et l'athérosclérose.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)